Acquired Madelung's deformity in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis.

1. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis Jr JC, Dijkmans B, et al. ASAS/EULAR recommendations for themanagement of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442–52. 2. Kobayashi S,HarigaiM,MozaffarianN,PanganAL, SharmaS,BrownLS, et al. Amulticenter, open-label, efficacy, pharmacokinetic, and safety studyof adalimumab in Japanese patientswith ankylosing spondylitis. Mod Rheumatol. 2012;22:589–97. 3. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol. 2008;126: 13–30. 4. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, et al., CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1612–7. 5. Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A. Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther. 2011;49:38–40. 6. Efe C. Drug induced autoimmune hepatitis and TNFblocking agents: is there a real relationship? Autoimmunity Rev. 2013;12:337–9. 7. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–46. 8. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757–90.